TLTFF (Theralase Technologies) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies 3-Year Revenue Growth Rate?

Theralase Technologies's Revenue per Share for the three months ended in Sep. 2024 was $0.00.

During the past 12 months, Theralase Technologies's average Revenue per Share Growth Rate was -20.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -15.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -17.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Theralase Technologies was 250.30% per year. The lowest was -35.90% per year. And the median was -10.60% per year.

Competitive Comparison of Theralase Technologies's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Theralase Technologies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's 3-Year Revenue Growth Rate falls into.

Theralase Technologies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Theralase Technologies (OTCPK:TLTFF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Theralase Technologies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

TTX:Germany TTX:Germany TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.